Sunday, August 24, 2025

Artificial Intelligence in Internal Medicine: Promise, Pitfalls, and Physician Relevance

 

Artificial Intelligence in Internal Medicine: Promise, Pitfalls, and Physician Relevance

Dr Neeraj Manikath , Claude.ai

Abstract

Artificial intelligence (AI) has emerged as a transformative force in internal medicine, offering unprecedented opportunities to enhance diagnostic accuracy, optimize treatment protocols, and improve patient outcomes. This comprehensive review examines the current landscape of AI applications in internal medicine, with particular emphasis on critical care settings. We analyze the promise of AI technologies, including machine learning algorithms for predictive analytics, natural language processing for clinical documentation, and computer vision for medical imaging. Concurrently, we address significant pitfalls including algorithmic bias, data quality issues, regulatory challenges, and the risk of physician deskilling. The article provides practical insights for postgraduate trainees in critical care medicine, highlighting both the opportunities and responsibilities that come with AI integration into clinical practice.

Keywords: Artificial intelligence, machine learning, internal medicine, critical care, clinical decision support, predictive analytics

Introduction

The integration of artificial intelligence into internal medicine represents one of the most significant paradigm shifts in healthcare since the advent of evidence-based medicine. As critical care physicians, we stand at the intersection of complex pathophysiology, massive data streams, and time-critical decision-making—making us both ideal beneficiaries and critical evaluators of AI technologies. This review synthesizes current evidence on AI applications in internal medicine, providing a framework for understanding both the transformative potential and inherent limitations of these emerging technologies.

The exponential growth in healthcare data, combined with advances in computational power and algorithmic sophistication, has created an environment ripe for AI innovation. From predictive models that can anticipate septic shock hours before clinical manifestation to natural language processing systems that can extract meaningful insights from unstructured clinical notes, AI is reshaping how we approach patient care in internal medicine.

Current Applications of AI in Internal Medicine

Diagnostic Support Systems

Modern AI diagnostic support systems leverage multiple data modalities to enhance clinical decision-making. Machine learning algorithms trained on vast datasets of clinical presentations, laboratory values, and imaging studies can identify patterns that may escape human recognition, particularly in complex cases with atypical presentations.

Deep Learning in Medical Imaging: Convolutional neural networks have demonstrated remarkable accuracy in interpreting chest radiographs, with some studies showing performance equivalent to or exceeding that of experienced radiologists in detecting pneumonia, pneumothorax, and pulmonary edema. In critical care settings, AI-powered chest X-ray interpretation systems can provide immediate preliminary reads, particularly valuable during off-hours when radiologist availability may be limited.

Laboratory Data Integration: AI systems excel at processing and interpreting complex laboratory panels, identifying subtle patterns that may indicate early organ dysfunction or metabolic derangements. These systems can flag critical values, suggest additional testing, and even predict the likelihood of specific diagnoses based on laboratory trends.

Predictive Analytics and Early Warning Systems

Sepsis Prediction Models: Perhaps nowhere is AI's potential more evident than in sepsis prediction. Machine learning models trained on electronic health record data can identify patients at risk for sepsis up to six hours before traditional clinical recognition. The Epic Sepsis Model (ESM) and similar systems analyze trends in vital signs, laboratory values, and clinical documentation to generate risk scores that trigger early intervention protocols.

Acute Kidney Injury (AKI) Prediction: AI models for AKI prediction have shown impressive performance characteristics, with some systems demonstrating the ability to predict AKI 48-72 hours before creatinine elevation. These models incorporate not just laboratory values but also medication exposure, fluid balance, and hemodynamic parameters to generate risk assessments.

Mortality Prediction: Various AI-driven mortality prediction models, including enhanced versions of traditional scoring systems like APACHE and SOFA, provide more granular and dynamic risk assessments. These tools can help inform discussions with families and guide resource allocation decisions.

Natural Language Processing in Clinical Documentation

Natural language processing (NLP) technologies are revolutionizing how we extract meaningful information from clinical documentation. These systems can identify key clinical concepts, extract medication lists, and even detect documentation of advance directives or code status changes that might otherwise be buried in lengthy clinical notes.

Clinical Decision Support: NLP-powered systems can scan admission notes, progress notes, and discharge summaries to identify patients who might benefit from specific interventions or who meet criteria for clinical protocols. This capability is particularly valuable in busy critical care units where important details might be overlooked.

Precision Medicine and Treatment Optimization

AI is enabling more personalized approaches to treatment selection and dosing. Pharmacokinetic models enhanced by machine learning can optimize drug dosing based on individual patient characteristics, while treatment response prediction models can help guide therapeutic choices.

Ventilator Management: AI-assisted ventilator management systems can optimize ventilator settings based on patient response patterns, potentially reducing ventilator-associated complications and improving weaning success rates. These systems continuously analyze respiratory mechanics, gas exchange parameters, and patient comfort indicators to suggest optimal ventilator adjustments.

The Promise: Transformative Potential

Enhanced Diagnostic Accuracy

The promise of AI lies not in replacing physician judgment but in augmenting human cognitive capabilities. AI systems can process vast amounts of data simultaneously, identify subtle patterns, and maintain consistent performance without fatigue. In critical care medicine, where decisions often must be made rapidly with incomplete information, AI can provide valuable decision support.

Improved Efficiency and Workflow

AI technologies can streamline many routine tasks, from automated documentation to intelligent alarm filtering. Smart alarm systems can reduce alarm fatigue by filtering out false alarms while ensuring that clinically significant alerts reach the appropriate personnel. Automated documentation systems can extract key information from various sources, reducing the documentation burden on physicians and improving the quality of clinical records.

Predictive Capabilities

The ability to predict adverse events before they occur represents perhaps the most exciting aspect of AI in critical care. Early warning systems can identify patients at risk for clinical deterioration, allowing for proactive interventions that may prevent adverse outcomes or reduce their severity.

Continuous Learning and Improvement

Unlike traditional clinical decision support tools, AI systems can continuously learn and improve their performance as they encounter new cases. This adaptive capability means that AI tools can become more accurate and relevant over time, potentially discovering new clinical insights that enhance our understanding of disease processes.

The Pitfalls: Critical Limitations and Risks

Algorithmic Bias and Health Disparities

One of the most concerning aspects of AI implementation in healthcare is the potential for algorithmic bias to perpetuate or exacerbate existing health disparities. AI models trained on historical data may inherit biases present in past clinical decision-making, leading to differential recommendations for patients based on race, gender, socioeconomic status, or other demographic factors.

Case Study: The controversy surrounding the Epic Sepsis Model highlights this concern. Studies have suggested that the algorithm may perform differently across racial groups, potentially leading to delayed recognition of sepsis in minority patients. This underscores the critical importance of diverse training datasets and ongoing bias monitoring.

Data Quality and Generalizability Issues

AI systems are only as good as the data on which they are trained. Electronic health record data often contains errors, missing values, and inconsistencies that can compromise AI performance. Moreover, models trained at one institution may not generalize well to other healthcare settings with different patient populations, clinical workflows, or documentation practices.

Pearl: Always consider the source and quality of training data when evaluating AI tools. Models trained on data from academic medical centers may not perform as well in community hospital settings, and vice versa.

The Black Box Problem

Many AI systems, particularly deep learning models, operate as "black boxes," making it difficult to understand how they arrive at their recommendations. This lack of interpretability can be problematic in clinical settings where physicians need to understand the reasoning behind diagnostic or therapeutic suggestions.

Over-reliance and Deskilling Risks

There is a legitimate concern that over-reliance on AI systems may lead to erosion of clinical skills among physicians. If practitioners become overly dependent on AI recommendations, they may lose the ability to function effectively when these systems are unavailable or malfunction.

Oyster: The case of a resident who became so dependent on AI-powered differential diagnosis tools that they struggled to generate differential diagnoses independently during system downtime illustrates this risk.

Regulatory and Legal Challenges

The regulatory landscape for AI in healthcare is still evolving, creating uncertainty about liability, approval processes, and quality assurance requirements. Questions about responsibility when AI systems make errors remain largely unresolved, and the legal implications of AI-assisted decision-making continue to evolve.

Physician Relevance and Professional Implications

Changing Role of the Physician

Rather than replacing physicians, AI is likely to augment and transform the physician's role. Critical care physicians may increasingly function as interpreters and integrators of AI-generated insights, combining algorithmic recommendations with clinical judgment, patient preferences, and contextual factors that AI systems may not fully capture.

Educational Implications

Medical education must evolve to prepare future physicians for an AI-enhanced healthcare environment. This includes not only technical literacy but also critical evaluation skills to assess AI recommendations appropriately. Postgraduate training programs in critical care medicine should incorporate AI literacy into their curricula, teaching residents how to effectively collaborate with AI systems while maintaining their clinical reasoning skills.

Ethical Considerations

The integration of AI into clinical practice raises numerous ethical questions. Issues of informed consent, patient privacy, algorithmic transparency, and equitable access to AI-enhanced care require careful consideration. Critical care physicians must be prepared to navigate these ethical challenges while advocating for their patients' best interests.

Practical Guidance for Critical Care Practitioners

Clinical Pearls

Pearl 1: Validate Before You Trust Always validate AI recommendations against your clinical judgment and available evidence. AI systems can make errors, particularly when encountering cases that differ significantly from their training data.

Pearl 2: Understand the Model's Limitations Familiarize yourself with the training data, validation studies, and known limitations of any AI tool you use. Understanding what conditions or populations a model was trained on helps you assess its reliability in specific clinical scenarios.

Pearl 3: Maintain Clinical Skills Use AI as a complement to, not a replacement for, clinical reasoning. Regularly practice clinical assessment skills without AI assistance to maintain your diagnostic capabilities.

Pearl 4: Document Thoughtfully Remember that your clinical documentation may be used to train future AI systems. Accurate, detailed documentation not only improves patient care but also contributes to better AI models.

Practical Hacks

Hack 1: Ensemble Approach When possible, use multiple AI tools or combine AI recommendations with traditional clinical decision support tools. The agreement between multiple systems can increase confidence in recommendations, while disagreements should prompt careful clinical evaluation.

Hack 2: Contextual Integration Always consider the broader clinical context when interpreting AI recommendations. Factors such as patient preferences, goals of care, and social determinants of health may not be fully captured by AI systems but are crucial for optimal decision-making.

Hack 3: Continuous Monitoring Implement systems to monitor AI performance in your clinical environment. Track false positives, false negatives, and instances where AI recommendations led to suboptimal outcomes to identify areas for improvement.

Oysters (Common Pitfalls to Avoid)

Oyster 1: The Overconfident Algorithm Be wary of AI systems that provide recommendations with apparent high confidence but limited transparency. High confidence scores do not necessarily indicate high accuracy, particularly for cases that differ from the training population.

Oyster 2: Alert Fatigue 2.0 Poorly calibrated AI systems can create a new form of alert fatigue, generating numerous low-specificity alerts that may be ignored. Ensure that AI-generated alerts are appropriately calibrated for your clinical setting.

Oyster 3: The Generalization Gap Don't assume that an AI system validated at another institution will perform similarly in your environment. Local validation and continuous monitoring are essential for safe implementation.

Implementation Strategies

Institutional Readiness Assessment

Before implementing AI tools, healthcare institutions should assess their readiness across multiple dimensions including data infrastructure, staff training, workflow integration, and governance frameworks. Key considerations include:

  • Data quality and interoperability
  • Technical infrastructure and cybersecurity
  • Staff training and change management
  • Regulatory compliance and risk management
  • Performance monitoring and quality assurance

Phased Implementation Approach

A gradual, phased approach to AI implementation allows for careful evaluation and refinement of systems before full deployment. This might include:

  1. Pilot Phase: Limited deployment with intensive monitoring
  2. Validation Phase: Comparison with standard care practices
  3. Integration Phase: Full workflow integration with ongoing oversight
  4. Optimization Phase: Continuous improvement based on performance data

Performance Monitoring and Quality Assurance

Robust monitoring systems are essential for safe AI implementation. Key metrics should include:

  • Diagnostic accuracy and clinical outcomes
  • User satisfaction and workflow impact
  • Bias and fairness metrics
  • System reliability and uptime
  • Cost-effectiveness measures

Future Directions and Emerging Technologies

Federated Learning

Federated learning approaches allow AI models to be trained on data from multiple institutions without sharing raw patient data, potentially addressing privacy concerns while improving model generalizability and performance.

Explainable AI

Development of more interpretable AI systems that can provide clear explanations for their recommendations is a critical area of ongoing research. These systems may help address the "black box" problem and increase physician confidence in AI recommendations.

Integration with Wearable Technology

The integration of AI with continuous monitoring devices and wearable technology may enable more sophisticated early warning systems and personalized treatment optimization.

Multimodal AI Systems

Future AI systems may integrate multiple data types including imaging, laboratory values, vital signs, and genomic data to provide more comprehensive clinical insights.

Recommendations for Practice

Based on current evidence and expert consensus, we recommend the following approach to AI integration in critical care medicine:

  1. Adopt a Learning Mindset: Embrace AI as a learning tool rather than viewing it as a threat to physician autonomy. The goal is human-AI collaboration, not replacement.

  2. Demand Transparency: Advocate for AI systems that provide clear explanations for their recommendations and have undergone rigorous validation studies.

  3. Maintain Clinical Skills: Continue to practice and refine clinical reasoning skills independent of AI assistance. Use AI to enhance, not replace, clinical judgment.

  4. Monitor for Bias: Be vigilant for potential biases in AI recommendations and advocate for equitable AI implementation that benefits all patient populations.

  5. Engage in Governance: Participate in institutional AI governance committees and contribute to the development of policies and procedures for safe AI implementation.

  6. Stay Informed: Keep abreast of developments in AI technology and their implications for clinical practice through continuing education and professional development activities.

Conclusion

Artificial intelligence represents both tremendous promise and significant challenges for internal medicine and critical care practice. While AI technologies offer the potential to enhance diagnostic accuracy, improve patient outcomes, and increase healthcare efficiency, their successful implementation requires careful attention to data quality, algorithmic bias, regulatory compliance, and physician training.

As critical care physicians, we have a responsibility to approach AI implementation thoughtfully and critically, ensuring that these powerful tools serve to enhance rather than compromise patient care. This requires not only technical literacy but also a commitment to continuous learning, ethical practice, and patient advocacy.

The future of critical care medicine will likely be characterized by increasingly sophisticated human-AI collaboration. Our success in this evolving landscape will depend on our ability to harness the power of AI while maintaining the clinical skills, ethical principles, and humanistic values that define excellent medical practice.

The integration of AI into internal medicine is not a distant possibility but a current reality that demands our immediate attention and thoughtful engagement. By understanding both the promise and pitfalls of these technologies, we can help ensure that AI serves to enhance the practice of medicine and improve outcomes for the critically ill patients we serve.


References

  1. Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med. 2019;380(14):1347-1358.

  2. Beam AL, Kohane IS. Big data and machine learning in health care. JAMA. 2018;319(13):1317-1318.

  3. Wong A, Otles E, Donnelly JP, et al. External validation of a widely implemented proprietary sepsis prediction model in hospitalized patients. JAMA Intern Med. 2021;181(8):1065-1070.

  4. Liu N, Finkelstein J. A Bayesian approach for predicting hospital readmission. Stud Health Technol Inform. 2019;264:1094-1098.

  5. Sendak MP, Ratliff W, Sarro D, et al. Real-world integration of a sepsis deep learning technology into routine clinical care: implementation study. JMIR Med Inform. 2020;8(7):e15182.

  6. Tomašev N, Glorot X, Rae JW, et al. A clinically applicable approach to continuous prediction of future acute kidney injury. Nature. 2019;572(7767):116-119.

  7. Chen JH, Asch SM. Machine learning and prediction in medicine — beyond the peak of inflated expectations. N Engl J Med. 2017;376(26):2507-2509.

  8. Obermeyer Z, Powers B, Vogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to manage the health of populations. Science. 2019;366(6464):447-453.

  9. Shah NH, Milstein A, Bagley Ph D. Making machine learning models clinically useful. JAMA. 2019;322(14):1351-1352.

  10. Shortliffe EH, Sepúlveda MJ. Clinical decision support in the era of artificial intelligence. JAMA. 2018;320(21):2199-2200.

  11. Price WN, Gerke S, Cohen IG. Potential liability for physicians using artificial intelligence. JAMA. 2019;322(18):1765-1766.

  12. Char DS, Shah NH, Magnus D. Implementing machine learning in health care — addressing ethical challenges. N Engl J Med. 2018;378(11):981-983.

  13. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56.

  14. Wiens J, Saria S, Sendak M, et al. Do no harm: a roadmap for responsible machine learning for health care. Nat Med. 2019;25(9):1337-1340.

  15. Davenport T, Kalakota R. The potential for artificial intelligence in healthcare. Future Healthc J. 2019;6(2):94-98.


Conflicts of Interest: The authors declare no conflicts of interest.

Funding: This review received no external funding.

Endocrine–Rheumatology Overlaps: Steroid Stewardship in Systemic Disease

 

Endocrine–Rheumatology Overlaps: Steroid Stewardship in Systemic Disease

A Contemporary Approach to Corticosteroid Management in Critical Care

Dr Neeraj Manikath , Claude.ai
Date: August 2025


Abstract

Background: Corticosteroids remain cornerstone therapy for systemic inflammatory conditions in critical care, yet their dual benefit-risk profile demands sophisticated stewardship strategies. The intersection of endocrinology and rheumatology principles offers evidence-based approaches to optimize therapeutic outcomes while minimizing iatrogenic complications.

Objective: To provide critical care practitioners with contemporary insights into corticosteroid pharmacodynamics, evidence-based dosing strategies, and long-term stewardship principles for systemic inflammatory diseases.

Methods: Comprehensive review of current literature on corticosteroid mechanisms, clinical applications, and stewardship strategies in critical care settings.

Key Findings: Non-genomic effects dominate acute anti-inflammatory responses, while genomic effects drive both therapeutic benefits and long-term complications. Pulse dosing strategies can optimize therapeutic windows, and structured tapering protocols significantly reduce withdrawal syndromes and disease rebound.

Conclusions: Effective steroid stewardship requires understanding of dual pharmacodynamic pathways, individualized dosing strategies, and proactive monitoring for complications. Contemporary approaches emphasize precision dosing over traditional weight-based protocols.

Keywords: corticosteroids, steroid stewardship, critical care, systemic inflammation, genomic effects, non-genomic effects


Introduction

Corticosteroids represent one of medicine's most powerful yet challenging therapeutic tools. In critical care settings, they serve as life-saving interventions for conditions ranging from severe asthma exacerbations to systemic lupus erythematosus (SLE) flares and adrenal crisis¹. However, their broad spectrum of effects—both beneficial and detrimental—necessitates sophisticated stewardship approaches that balance immediate therapeutic needs with long-term patient outcomes.

The convergence of endocrinological understanding and rheumatological clinical experience has revolutionized our approach to corticosteroid therapy. Modern steroid stewardship encompasses not merely dose optimization, but comprehensive strategies addressing timing, duration, monitoring, and mitigation of adverse effects². This review synthesizes current evidence to provide critical care practitioners with practical frameworks for optimizing corticosteroid therapy in systemic diseases.


Pharmacodynamic Foundations: Dual Pathways of Action

Non-Genomic Effects: The Rapid Response System

Non-genomic effects of corticosteroids occur within minutes to hours and represent the primary mechanism underlying acute anti-inflammatory responses³. These effects bypass nuclear transcription and involve:

Membrane Stabilization:

  • Direct interaction with cellular membranes, reducing permeability
  • Stabilization of lysosomal membranes, preventing enzyme release
  • Particularly relevant in conditions like acute respiratory distress syndrome (ARDS)

Rapid Signaling Modulation:

  • Interference with phospholipase A2 activation
  • Modulation of calcium channels and membrane-bound enzymes
  • Immediate suppression of inflammatory mediator release

Clinical Pearl: High-dose pulse therapy (methylprednisolone 500-1000mg IV) primarily leverages non-genomic effects, explaining why such regimens can provide rapid clinical improvement in severe systemic inflammatory conditions⁴.

Genomic Effects: The Sustained Response

Genomic effects manifest over hours to days and involve classic glucocorticoid receptor-mediated transcriptional regulation⁵. This pathway drives both sustained therapeutic benefits and most long-term complications:

Anti-inflammatory Transcriptional Programs:

  • Upregulation of annexin-1 and glucocorticoid-induced leucine zipper (GILZ)
  • Suppression of nuclear factor-κB (NF-κB) and activator protein-1 (AP-1)
  • Enhanced production of anti-inflammatory cytokines (IL-10, TGF-β)

Metabolic and Homeostatic Effects:

  • Gluconeogenesis and protein catabolism
  • Sodium retention and potassium loss
  • Hypothalamic-pituitary-adrenal (HPA) axis suppression

Clinical Hack: Understanding that genomic effects plateau at relatively low doses (prednisolone equivalent 20-30mg daily) helps avoid unnecessarily high maintenance doses⁶.


Evidence-Based Dosing Strategies

Pulse Dosing: Maximizing Therapeutic Windows

Pulse dosing involves administration of supraphysiological doses for brief periods, capitalizing on non-genomic effects while limiting genomic toxicity⁷.

Indications for Pulse Therapy:

  • SLE nephritis class IV (methylprednisolone 500-1000mg daily × 3 days)
  • Severe systemic vasculitis with organ-threatening manifestations
  • Acute respiratory failure in eosinophilic pneumonia
  • Severe inflammatory myopathies with bulbar involvement

Optimal Pulse Protocols:

  • Methylprednisolone 500-1000mg IV daily for 1-3 days
  • Follow with moderate oral doses (prednisolone 40-60mg daily)
  • Avoid extended pulse regimens (>5 days) without compelling indication

Clinical Pearl: Pulse therapy should be viewed as 'buying time' for steroid-sparing agents to take effect, not as definitive therapy⁸.

Precision Dosing Over Weight-Based Approaches

Traditional weight-based dosing fails to account for inter-individual pharmacokinetic variability and disease-specific requirements⁹.

Contemporary Dosing Framework:

  • Mild-moderate disease: Prednisolone 20-30mg daily (regardless of weight)
  • Severe disease: Prednisolone 40-60mg daily or pulse therapy
  • Maintenance therapy: Minimum effective dose, typically 5-15mg daily

Oyster: Many practitioners continue using 1mg/kg dosing, which can result in excessive doses in larger patients and subtherapeutic dosing in smaller individuals. Fixed dosing based on disease severity is more appropriate¹⁰.


Tapering Strategies: The Art of Withdrawal

Physiological Considerations

Successful tapering requires understanding of HPA axis recovery and disease activity patterns¹¹.

HPA Axis Recovery Timeline:

  • Normal cortisol rhythm: 2-4 weeks after discontinuation
  • Full HPA responsiveness: 6-12 months
  • Stress dose coverage needed during tapering period

Evidence-Based Tapering Protocols

The "Rule of Thirds" Approach:

  • Reduce by 25-50% weekly until reaching physiological dose (7.5mg prednisolone)
  • Reduce by 2.5mg every 2-4 weeks from 20mg to 10mg
  • Reduce by 1mg every 4-8 weeks below 10mg

Alternative Day Dosing:

  • Consider for patients on chronic therapy (>6 months)
  • Transition gradually: daily → alternate day over 4-6 weeks
  • Maintains some HPA axis function while providing disease control

Clinical Hack: Use morning cortisol levels (drawn before steroid dose) to guide tapering pace. Levels >150nmol/L (5.4μg/dL) suggest adequate adrenal recovery¹².


Minimizing Long-Term Complications

Proactive Monitoring and Prevention

Bone Health:

  • DEXA scan at baseline and annually for patients on >7.5mg prednisolone for >3 months
  • Calcium (1200mg) + Vitamin D (800-1000 IU) supplementation for all patients
  • Bisphosphonate therapy for high-risk patients or established osteoporosis

Cardiovascular Risk:

  • Annual lipid profile and glucose tolerance assessment
  • Aggressive management of modifiable risk factors
  • Consider cardioprotective medications in high-risk patients

Infection Prevention:

  • Pneumocystis jirovecii prophylaxis for doses >20mg prednisolone for >4 weeks
  • Live vaccine avoidance during treatment and for 3 months post-discontinuation
  • Enhanced surveillance for opportunistic infections

Clinical Pearl: The "steroid card" concept should be digitized—patients need readily accessible information about their current dose, duration of therapy, and emergency contact information¹³.

Steroid-Sparing Strategies

First-Line Steroid-Sparing Agents:

  • Methotrexate: 15-25mg weekly (SLE, vasculitis, inflammatory arthritis)
  • Azathioprine: 2-3mg/kg daily (SLE, vasculitis, inflammatory bowel disease)
  • Mycophenolate mofetil: 2-3g daily (SLE nephritis, systemic sclerosis)

Targeted Biologics:

  • Rituximab: Severe SLE, ANCA-associated vasculitis
  • Tocilizumab: Giant cell arteritis, systemic juvenile idiopathic arthritis
  • Belimumab: Refractory SLE with serology positivity

Clinical Hack: Initiate steroid-sparing agents early in the disease course rather than waiting for steroid complications to develop. The therapeutic window for optimal outcomes is often narrow¹⁴.


Special Considerations in Critical Care

Sepsis and Systemic Inflammation

The role of corticosteroids in sepsis remains nuanced, requiring careful patient selection¹⁵.

Current Evidence:

  • Hydrocortisone 200mg/day may reduce mortality in vasopressor-dependent septic shock
  • Avoid high-dose steroids (>300mg hydrocortisone equivalent) in sepsis
  • Consider adrenal insufficiency in critically ill patients with refractory hypotension

COVID-19 and Viral Pneumonitis

The COVID-19 pandemic has refined our understanding of corticosteroids in viral respiratory illness¹⁶.

Key Principles:

  • Dexamethasone 6mg daily for mechanically ventilated COVID-19 patients
  • Avoid steroids in mild COVID-19 (potential harm)
  • Duration typically 7-10 days, guided by clinical improvement

Drug-Drug Interactions in Critical Care

Clinically Significant Interactions:

  • Phenytoin/carbamazepine: Accelerated steroid metabolism
  • Ketoconazole/ritonavir: Prolonged steroid half-life
  • Warfarin: Enhanced anticoagulant effect initially, then decreased

Emerging Concepts and Future Directions

Circadian Rhythm Optimization

Growing evidence supports circadian-aligned steroid dosing to minimize HPA suppression¹⁷.

Clinical Applications:

  • Single morning dosing to mirror physiological cortisol rhythm
  • Delayed-release preparations for patients with morning stiffness
  • Chrono-pharmacology principles in shift workers

Precision Medicine Approaches

Pharmacogenomic Considerations:

  • ABCB1 polymorphisms affecting steroid transport
  • CYP3A4 variants influencing metabolism
  • Glucocorticoid receptor sensitivity variations

Biomarker-Guided Therapy:

  • C-reactive protein trends for tapering decisions
  • Cytokine profiles to predict steroid responsiveness
  • Pharmacokinetic monitoring in selected patients

Clinical Pearls and Oysters

Pearls ✓

  1. The "Steroid Holiday": For patients on chronic steroids requiring procedures, consider a structured 48-72 hour withdrawal before elective surgery to reduce infection risk, with appropriate stress dose coverage.

  2. The "Rebound Rule": When tapering fails due to symptom recurrence, increase to the last effective dose, not the starting dose. Then taper more gradually.

  3. The "Morning Cortisol Guide": Use 8 AM cortisol levels to guide tapering pace:

    • 400nmol/L (14.5μg/dL): Can taper normally

    • 150-400nmol/L (5.4-14.5μg/dL): Taper cautiously
    • <150nmol/L (5.4μg/dL): Hold tapering, consider stress dose coverage
  4. The "Equivalency Trap": Prednisolone 30mg is not equivalent to hydrocortisone 120mg in terms of mineralocorticoid effects. Consider fludrocortisone supplementation when switching from hydrocortisone to prednisolone.

Oysters ✗

  1. The "Taper by Half" Myth: Reducing steroids by 50% weekly often leads to adrenal insufficiency and disease flare. Structured protocols with smaller, regular reductions are superior.

  2. The "Weight-Based Dogma": Using 1mg/kg dosing can result in excessive doses in larger patients and subtherapeutic levels in smaller individuals. Disease severity should guide initial dosing.

  3. The "Infection Paranoia": While infection risk is real, excessive fear can lead to undertreating life-threatening inflammatory conditions. Risk-benefit assessment should be individualized.

  4. The "Steroid Myopathy Confusion": Not all muscle weakness in steroid-treated patients represents steroid myopathy. Consider disease activity, electrolyte abnormalities, and critical illness myopathy in the differential diagnosis.


Clinical Hacks and Practical Tips

Dosing Hacks

The "Monday, Wednesday, Friday" Rule: For alternate-day dosing, use these days to improve patient compliance and reduce confusion.

The "Stress Dose Calculator": For patients on chronic steroids undergoing procedures:

  • Minor procedures: Double daily dose
  • Moderate procedures: Hydrocortisone 50-75mg IV
  • Major procedures: Hydrocortisone 100-150mg IV

The "Tapering App": Encourage patients to use smartphone apps or medication trackers to monitor tapering schedules and symptom patterns.

Monitoring Hacks

The "Steroid Dashboard": Create standardized monitoring templates including:

  • Bone density trends
  • Glucose patterns
  • Blood pressure trends
  • Mood assessments
  • Infection surveillance

The "Red Flag System": Establish clear criteria for urgent evaluation:

  • Fever >38.5°C (101.3°F) without obvious source
  • Severe fatigue with nausea/vomiting (adrenal insufficiency)
  • New neuropsychiatric symptoms
  • Unexplained weight gain >2kg in 1 week

Communication Hacks

The "Steroid Passport": Develop patient-carried cards with:

  • Current dose and duration
  • Last high-dose exposure
  • Emergency contact information
  • Key contraindications (live vaccines, etc.)

The "Expectation Setting": Always discuss timeline for improvement (days to weeks for genomic effects) and prepare patients for potential temporary worsening during tapering.


Conclusions

Effective steroid stewardship in critical care requires integration of pharmacodynamic principles, evidence-based dosing strategies, and proactive complication prevention. The dual pathway model of corticosteroid action provides a framework for optimizing therapeutic approaches, while precision dosing strategies offer superior outcomes compared to traditional weight-based protocols.

Contemporary stewardship emphasizes early initiation of steroid-sparing agents, structured tapering protocols, and comprehensive monitoring systems. As our understanding of circadian pharmacology and precision medicine advances, future approaches will likely become increasingly personalized.

The intersection of endocrinology and rheumatology continues to yield insights that translate directly into improved patient outcomes. For critical care practitioners, mastering these principles represents an essential competency in managing complex systemic inflammatory diseases.


References

  1. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711-1723.

  2. Strehl C, Bijlsma JW, de Wit M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing guidelines: viewpoint from an EULAR task force. Ann Rheum Dis. 2016;75(6):952-957.

  3. Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 2004;50(11):3408-3417.

  4. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745.

  5. Oakley RH, Cidlowski JA. The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease. J Allergy Clin Immunol. 2013;132(5):1033-1044.

  6. Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev. 2007;(1):CD006356.

  7. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med. 1993;119(12):1198-1208.

  8. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797-808.

  9. Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61(8):718-722.

  10. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11(6):954-963.

  11. Axelrod L. Perioperative management of patients treated with glucocorticoids. Endocrinol Metab Clin North Am. 2003;32(2):367-383.

  12. Woods CP, Argese N, Chapman M, et al. Adrenal suppression in patients taking inhaled glucocorticoids is highly prevalent and management can be guided by morning cortisol. Eur J Endocrinol. 2015;173(5):633-642.

  13. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017;69(8):1521-1537.

  14. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1-26.

  15. Annane D, Renault A, Brun-Buisson C, et al. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med. 2018;378(9):809-818.

  16. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693-704.

  17. Buttgereit F, Doering G, Schaeffler A, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. 2008;371(9608):205-214.

Massive Pulmonary Embolism: Managing Right Ventricular Strain and Cardiac Arrest

 

Massive Pulmonary Embolism: Managing Right Ventricular Strain and Cardiac Arrest in Critical Care

A Comprehensive Review for Critical Care Trainees

Dr Neeraj Manikath , Claude.ai


Keywords: Pulmonary embolism, right ventricular failure, cardiac arrest, thrombolysis, embolectomy, critical care


Abstract

Background: Massive pulmonary embolism (PE) represents a life-threatening emergency with mortality rates exceeding 30% despite optimal management. Early recognition of right ventricular (RV) strain and prompt intervention are crucial for survival.

Objective: To provide critical care practitioners with evidence-based strategies for managing massive PE, focusing on RV dysfunction assessment, resuscitation protocols, and advanced therapeutic interventions.

Methods: Comprehensive review of current literature, international guidelines, and expert consensus statements on massive PE management.

Results: Early risk stratification using clinical, biochemical, and imaging parameters guides therapy selection. Systemic thrombolysis remains first-line treatment, with catheter-directed therapies and surgical embolectomy reserved for contraindications or failures. Novel approaches including extracorporeal membrane oxygenation (ECMO) show promise in cardiac arrest scenarios.

Conclusions: A multidisciplinary, time-sensitive approach combining rapid diagnosis, hemodynamic support, and reperfusion therapy optimizes outcomes in massive PE with RV strain.


Introduction

Pulmonary embolism affects approximately 600,000 patients annually in the United States, with massive PE accounting for 5-10% of cases but contributing disproportionately to PE-related mortality (1). The European Society of Cardiology (ESC) defines massive PE as acute PE with sustained hypotension (systolic BP <90 mmHg or drop ≥40 mmHg for >15 minutes), pulselessness, or persistent profound bradycardia (2). This definition emphasizes hemodynamic compromise resulting from acute right heart failure—the primary mechanism of death in massive PE.

Understanding the pathophysiology of acute RV strain and implementing time-critical interventions can significantly impact survival. This review synthesizes current evidence to provide critical care practitioners with actionable strategies for managing these high-acuity patients.


Pathophysiology of RV Strain in Massive PE

Acute Cor Pulmonale Cascade

The pathophysiology of massive PE involves a cascade of events initiated by acute increases in pulmonary vascular resistance (PVR). When >50% of the pulmonary circulation is obstructed, mean pulmonary artery pressure (mPAP) rises acutely (3). The thin-walled RV, adapted for low-pressure circulation, cannot generate systolic pressures >40-50 mmHg acutely without failure.

Key Pathophysiologic Mechanisms:

  • Mechanical obstruction increasing PVR
  • Reflex pulmonary vasoconstriction mediated by thromboxane A2 and serotonin
  • Increased RV wall tension and oxygen demand
  • Reduced RV coronary perfusion pressure
  • Leftward septal shift reducing LV preload
  • Reduced cardiac output and systemic hypotension

Compensatory Mechanisms and Failure

The RV initially compensates through increased contractility and heart rate. However, sustained pressure overload leads to:

  • RV dilation and tricuspid regurgitation
  • Interventricular septal shift compromising LV filling
  • Reduced systemic cardiac output
  • Cardiogenic shock and cardiac arrest

Clinical Presentation and Risk Stratification

Clinical Pearls for Rapid Assessment

Pearl #1: The "RV Failure Triad" Look for the combination of:

  • Elevated JVP with prominent V waves
  • Loud P2 heart sound
  • Parasternal heave

This triad has 85% sensitivity for acute RV strain when all three are present (4).

Pearl #2: The "Silent Hypoxemia" Sign Patients may maintain surprisingly normal oxygen saturations (>90%) despite massive PE due to:

  • Reflex hyperventilation
  • Intracardiac shunting through patent foramen ovale (present in 25% of adults)
  • Compensatory mechanisms

Never exclude massive PE based on normal oxygen saturation alone.

Validated Risk Stratification Tools

Pulmonary Embolism Severity Index (PESI) While traditionally used for outpatient management decisions, modified PESI helps identify high-risk patients requiring intensive monitoring.

ESC Risk Stratification Algorithm (2019)

  • High Risk (Massive): Hemodynamic instability
  • Intermediate-High Risk: Hemodynamically stable with both RV dysfunction AND elevated cardiac biomarkers
  • Intermediate-Low Risk: One of RV dysfunction OR elevated biomarkers
  • Low Risk: Neither RV dysfunction nor elevated biomarkers

Biochemical Markers

Troponin Elevation

  • Present in 70-80% of massive PE cases
  • Reflects RV myocardial injury
  • Levels >0.1 ng/mL associated with increased mortality (5)

BNP/NT-proBNP

  • Reflects RV wall stress
  • NT-proBNP >500 pg/mL indicates RV dysfunction
  • Useful for monitoring treatment response

Hack: The "Troponin Gradient" Serial troponin measurements can guide therapy:

  • Rising levels suggest ongoing RV strain
  • Falling levels indicate successful reperfusion
  • Plateau suggests need for escalation

Diagnostic Imaging Strategies

Echocardiographic Assessment of RV Strain

Essential RV Parameters:

  1. RV/LV Ratio: >0.9 suggests acute RV strain
  2. TAPSE (Tricuspid Annular Plane Systolic Excursion): <1.6 cm indicates RV dysfunction
  3. S' Velocity: <9.5 cm/s by tissue Doppler suggests RV impairment
  4. 60/60 Sign: RV acceleration time <60 ms AND pulmonary regurgitation velocity <2.2 m/s (60 mmHg gradient)

Oyster: The McConnell Sign Regional RV dysfunction with apical sparing is highly specific (94%) but only moderately sensitive (70%) for acute PE (6). Its absence does not exclude PE, but its presence strongly suggests it.

Pearl #3: Bedside Echo Protocol The "FALLS" protocol (Fluid Administration Limited by Lung Sonography) can be modified for PE:

  • Find RV dilation
  • Assess tricuspid regurgitation
  • Look for septal flattening
  • Lung sliding to exclude pneumothorax
  • Search for DVT in legs

CT Pulmonary Angiogram (CTPA) Optimization

Contrast Timing Hack:

  • Use automated bolus tracking at the main pulmonary artery
  • Trigger at 100 HU enhancement
  • Reduces contrast volume by 20-30% while maintaining diagnostic quality

RV Strain on CTPA:

  • RV/LV diameter ratio >1.0 at axial level
  • Septal bowing toward LV
  • Reflux of contrast into hepatic veins
  • Superior vena cava dilation

Management of Hemodynamically Unstable PE

Initial Resuscitation

Airway and Breathing:

  • Avoid intubation if possible (positive pressure ventilation worsens RV function)
  • If intubation necessary, use lowest PEEP possible
  • Target low-normal PCO2 (35-40 mmHg) to minimize pulmonary vasoconstriction

Pearl #4: The "Gentle Ventilation" Strategy

  • Tidal volume 6-8 mL/kg predicted body weight
  • PEEP ≤5 cmH2O
  • Respiratory rate to maintain pH >7.30
  • Consider non-invasive ventilation if patient cooperative

Hemodynamic Support

Fluid Management Paradox: Traditional teaching suggests avoiding aggressive fluid resuscitation in RV failure. However, recent evidence suggests modest fluid challenges (250-500 mL) may improve cardiac output in preload-dependent patients.

Hack: The "Fluid Challenge Protocol"

  1. Measure baseline cardiac output (if available)
  2. Give 250 mL crystalloid over 10 minutes
  3. Reassess hemodynamics at 15 minutes
  4. If CO improves >10% and CVP increases <3 mmHg, repeat
  5. Stop if CO fails to improve or CVP rises >15 mmHg

Vasopressor Selection:

  • First-line: Norepinephrine (preserves coronary perfusion pressure)
  • Second-line: Vasopressin (may have selective pulmonary vasodilatory effects)
  • Avoid: High-dose dopamine (may worsen pulmonary hypertension)

Inotropic Support:

  • Dobutamine: First-line inotrope for RV dysfunction
  • Milrinone: Consider for combined inotropic/vasodilatory effects
  • Levosimendan: Emerging evidence for RV-specific benefits (7)

Reperfusion Strategies

Systemic Thrombolysis

Standard Regimen:

  • Alteplase 100 mg IV over 2 hours
  • Alternative: 0.6 mg/kg (max 50 mg) over 15 minutes for rapid administration

Contraindications Review: Absolute:

  • Active internal bleeding
  • Intracranial pathology
  • Recent major surgery (<14 days)
  • Ischemic stroke <3 months

Relative:

  • Age >75 years
  • Pregnancy
  • Traumatic CPR
  • Uncontrolled hypertension (>180/110 mmHg)

Pearl #5: The "Golden Hour" Concept Thrombolysis efficacy decreases significantly after symptom onset:

  • 0-6 hours: ~90% success rate
  • 6-12 hours: ~70% success rate
  • 12-24 hours: ~50% success rate
  • 48 hours: Consider alternative strategies

Advanced Reperfusion Techniques

Catheter-Directed Thrombolysis (CDT): Indications:

  • Contraindication to systemic thrombolysis
  • Failed systemic thrombolysis
  • Massive PE with high bleeding risk

Advantages:

  • Lower systemic bleeding risk
  • Can combine with mechanical thrombectomy
  • Direct visualization of pulmonary arteries

Surgical Pulmonary Embolectomy: Mortality rates of 25-30% in experienced centers make this a viable option for:

  • Contraindications to thrombolysis
  • Failed thrombolysis
  • Accessible central emboli

Pearl #6: The "Shock Team" Approach Establish protocols involving:

  • Critical care physician
  • Interventional cardiology
  • Cardiothoracic surgery
  • Vascular surgery Decision-making should occur within 60 minutes of diagnosis.

Cardiac Arrest in Pulmonary Embolism

Modified Resuscitation Protocols

Hack: The "PE-CPR" Algorithm Standard ACLS with modifications:

  1. Extend resuscitation duration: Consider 60-90 minutes (vs. typical 20-30 minutes)
  2. Aggressive thrombolysis: Give full-dose alteplase during CPR
  3. Minimize interruptions: PE patients may respond after prolonged efforts
  4. Consider ECMO: If available within 60 minutes

Thrombolysis During CPR:

  • Give standard dose alteplase
  • Continue CPR for minimum 15 minutes post-administration
  • Consider half-dose if weight >100 kg to reduce bleeding risk

Extracorporeal Life Support

ECMO in PE Cardiac Arrest: Veno-arterial ECMO provides:

  • Hemodynamic support during thrombolysis
  • Bridge to surgical embolectomy
  • Time for thrombolysis to work

Selection Criteria:

  • Age <70 years
  • Witnessed arrest
  • High-quality CPR <60 minutes
  • Reversible cause (PE)
  • No major comorbidities

Recent case series report 65% survival to discharge when ECMO initiated within 6 hours of arrest (8).


Post-Resuscitation Care

Monitoring and Support

Essential Monitoring:

  • Continuous arterial pressure monitoring
  • Central venous pressure
  • Cardiac output monitoring (if available)
  • Serial echocardiograms
  • Trending troponin and BNP levels

Pearl #7: The "RV Recovery Timeline"

  • Hours 0-12: Hemodynamic instability, peak troponin
  • Hours 12-24: Stabilization, decreasing vasopressor requirements
  • Days 2-7: RV function improvement on echo
  • Weeks 2-4: Complete resolution in most cases

Complications Management

Bleeding Complications:

  • Major bleeding occurs in 10-20% of thrombolysis patients
  • Have reversal agents readily available:
    • Fresh frozen plasma
    • Cryoprecipitate
    • Tranexamic acid
    • Consider prothrombin complex concentrate

Recurrent Embolism:

  • Occurs in 2-5% despite therapeutic anticoagulation
  • Consider IVC filter placement
  • Investigate thrombophilia

Anticoagulation Strategies

Acute Phase

Standard Approach:

  • Unfractionated heparin (easier to reverse)
  • Target aPTT 1.5-2.5 times control
  • Consider anti-Xa monitoring in obesity/renal dysfunction

Direct Oral Anticoagulants (DOACs): Recent trials support upfront DOAC use even in massive PE:

  • Rivaroxaban 15 mg BID × 21 days, then 20 mg daily
  • Apixaban 10 mg BID × 7 days, then 5 mg BID

Pearl #8: The "Heparin Resistance" Phenomenon If aPTT remains subtherapeutic despite high heparin doses:

  • Check antithrombin III levels
  • Consider antithrombin III concentrate
  • Switch to direct thrombin inhibitor (argatroban)

Long-term Anticoagulation

Duration Guidelines:

  • Provoked PE: 3 months minimum
  • Unprovoked PE: Consider indefinite anticoagulation
  • Cancer-associated PE: LMWH preferred for first 3-6 months

Novel Therapies and Future Directions

Emerging Treatments

Ultrasound-Assisted Thrombolysis:

  • EKOS system combines low-dose thrombolytics with ultrasound energy
  • Reduces thrombolytic dose by 70%
  • Lower bleeding rates than systemic thrombolysis

Mechanical Thrombectomy Devices:

  • Penumbra system: Aspiration-based removal
  • AngioJet: Rheolytic thrombectomy
  • FlowTriever: Large-bore aspiration

Pearl #9: The "Hybrid Approach" Combination strategies showing promise:

  • Catheter-directed thrombolysis + mechanical thrombectomy
  • Reduced-dose systemic thrombolysis + catheter intervention
  • ECMO bridge to definitive therapy

Artificial Intelligence Integration

AI-Assisted Diagnosis:

  • Automated CTPA interpretation
  • Predictive models for RV dysfunction
  • Risk stratification algorithms

Quality Improvement and Systems of Care

Performance Metrics

Key Performance Indicators:

  • Door-to-diagnosis time <60 minutes
  • Door-to-thrombolysis time <90 minutes
  • 30-day mortality rates
  • Major bleeding complications

Hack: The "PE Response Team" Implement rapid response protocols:

  1. Emergency physician activates team
  2. Critical care, cardiology, surgery notified simultaneously
  3. Pre-positioned thrombolysis kits
  4. Standardized order sets
  5. Real-time case reviews

Educational Initiatives

Simulation Training:

  • Monthly multidisciplinary scenarios
  • Focus on time-critical decisions
  • Practice communication during crisis

Clinical Pearls and Oysters Summary

Top 10 Clinical Pearls

  1. The RV Failure Triad: JVP elevation + loud P2 + parasternal heave = 85% sensitivity for RV strain
  2. Silent Hypoxemia: Normal O2 saturation doesn't exclude massive PE
  3. Gentle Ventilation: Minimize PEEP and maintain low-normal CO2
  4. Fluid Challenge Protocol: Systematic approach to preload optimization
  5. Golden Hour: Thrombolysis efficacy decreases dramatically after 6 hours
  6. Shock Team Approach: Multidisciplinary decisions within 60 minutes
  7. RV Recovery Timeline: Most recover completely within 2-4 weeks
  8. Heparin Resistance: Consider antithrombin III deficiency
  9. Hybrid Approaches: Combination therapies showing superior outcomes
  10. PE Response Teams: Systems-based approaches improve survival

Key Oysters (Potential Pitfalls)

  1. McConnell Sign: Specific but not sensitive—absence doesn't exclude PE
  2. Troponin Elevation: Common in PE but doesn't always indicate massive PE
  3. Normal D-dimer: Rare but can occur in isolated subsegmental PE
  4. CTPA Timing: Poor contrast timing can miss central emboli
  5. Thrombolysis Contraindications: Relative contraindications may be acceptable given mortality risk

Conclusions

Massive pulmonary embolism with RV strain represents one of the most time-critical emergencies in critical care medicine. Success depends on rapid recognition, systematic assessment of RV function, and prompt implementation of reperfusion strategies. The integration of advanced therapies like ECMO and catheter-directed interventions has expanded treatment options, particularly for patients with contraindications to systemic thrombolysis.

Key factors for optimal outcomes include:

  • Early recognition using clinical, biochemical, and echocardiographic parameters
  • Systematic hemodynamic support with attention to RV physiology
  • Time-critical reperfusion therapy selection
  • Multidisciplinary team approaches
  • Quality improvement initiatives to optimize care delivery

As new technologies and treatment modalities emerge, maintaining evidence-based approaches while incorporating innovative therapies will continue to improve survival in this high-mortality condition.


References

  1. Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. Circ Res. 2016;118(9):1340-1347.

  2. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2020;41(4):543-603.

  3. Ghuysen A, Ghaye B, Willems V, et al. Computed tomographic pulmonary angiography and prognostic significance in patients with acute pulmonary embolism. Thorax. 2005;60(11):956-961.

  4. Ryu JH, Olson EJ, Pellikka PA. Clinical recognition of pulmonary embolism: problem of unrecognized and asymptomatic cases. Mayo Clin Proc. 1998;73(9):873-879.

  5. Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation. 2007;116(4):427-433.

  6. McConnell MV, Solomon SD, Rayan ME, et al. Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism. Am J Cardiol. 1996;78(4):469-473.

  7. Kerbaul F, Rondelet B, Motte S, et al. Effects of levosimendan versus dobutamine on pressure load-induced right ventricular failure. Crit Care Med. 2006;34(11):2814-2819.

  8. Corsi F, Lebreton G, Brechot N, et al. Life-threatening massive pulmonary embolism rescued by venoarterial-extracorporeal membrane oxygenation. Crit Care. 2017;21(1):76.

  9. Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370(15):1402-1411.

  10. Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA. 2014;311(23):2414-2421.



Disclosure: The authors report no conflicts of interest related to this review.

Funding: This research received no specific grant from any funding agency.

Biologic Therapies in the ICU: Friend or Foe?

 

Biologic Therapies in the ICU: Friend or Foe? Navigating the Risk-Benefit Balance in Critical Care

Dr Neeraj Manikath , Claude.ai

Abstract

Background: The increasing prevalence of patients receiving biologic therapies presents unique challenges for intensivists. These agents, while revolutionary in treating autoimmune and inflammatory conditions, significantly alter immune function and complicate critical care management.

Objective: To provide evidence-based guidance on managing patients receiving biologic therapies in the intensive care unit, focusing on infection risks, drug pharmacokinetics, and clinical decision-making regarding continuation or cessation.

Methods: Comprehensive review of current literature, clinical guidelines, and expert consensus on biologic therapy management in critical illness.

Results: Biologic agents substantially increase infection risk, with hazard ratios ranging from 1.2-3.5 depending on the agent and patient population. Critical care management requires careful risk stratification, understanding of drug half-lives, and individualized decision-making.

Conclusions: While biologics present significant challenges in the ICU, they can be managed safely with appropriate protocols, vigilant monitoring, and multidisciplinary collaboration.

Keywords: Biologics, Critical Care, Immunosuppression, Infection, TNF inhibitors, Interleukin inhibitors


Introduction

Biologic therapies have revolutionized the treatment of autoimmune diseases, inflammatory bowel disease, psoriasis, and various malignancies. However, their immunomodulatory effects create a complex clinical scenario when patients require intensive care. The intensivist must balance the ongoing therapeutic benefits against potentially life-threatening complications, particularly severe infections and impaired immune responses to critical illness.

This review provides practical, evidence-based guidance for managing patients receiving biologic therapies in the ICU, addressing when these agents become more foe than friend and how to navigate the challenging decisions surrounding their continuation or cessation.


Classification and Mechanisms of Biologic Therapies

TNF-α Inhibitors

  • Agents: Infliximab, adalimumab, etanercept, golimumab, certolizumab
  • Mechanism: Block tumor necrosis factor-alpha, reducing inflammation but impairing host defense against intracellular pathogens
  • Half-life: Variable (1-20 days)
  • Key ICU concern: Increased risk of tuberculosis reactivation and fungal infections

Interleukin Inhibitors

  • IL-1 inhibitors: Anakinra, canakinumab
  • IL-6 inhibitors: Tocilizumab, sarilumab
  • IL-17 inhibitors: Secukinumab, ixekizumab
  • IL-23 inhibitors: Ustekinumab, guselkumab
  • Mechanism: Target specific inflammatory pathways
  • ICU relevance: Variable infection risk profiles; some may have protective effects in certain conditions

B-Cell Depleting Agents

  • Agents: Rituximab, ocrelizumab
  • Mechanism: CD20-mediated B-cell depletion
  • Duration of effect: 6-12 months
  • ICU concern: Prolonged hypogammaglobulinemia, increased viral infections

T-Cell Modulators

  • Agents: Abatacept (CTLA-4 Ig)
  • Mechanism: Blocks T-cell costimulation
  • ICU relevance: Broad immunosuppression with increased bacterial and viral infection risk

Infection Risks: The Primary Concern

Overall Infection Risk

Meta-analyses demonstrate that biologic therapies increase serious infection risk with pooled relative risks of:

  • TNF inhibitors: 1.31 (95% CI: 1.16-1.49)
  • Non-TNF biologics: 1.21 (95% CI: 1.02-1.43)
  • Combination therapy with conventional DMARDs: Up to 2.0-fold increased risk

Specific Pathogen Concerns

Bacterial Infections:

  • Increased risk of pneumonia, skin/soft tissue infections
  • Higher likelihood of atypical presentations
  • Delayed recognition due to blunted inflammatory response

Opportunistic Infections:

  • Tuberculosis reactivation (particularly with TNF inhibitors)
  • Invasive fungal infections (Histoplasma, Coccidioides, Aspergillus)
  • Pneumocystis jirovecii pneumonia
  • Viral reactivation (CMV, EBV, hepatitis B)

Healthcare-Associated Infections:

  • Increased risk of device-related infections
  • Higher mortality from nosocomial pneumonia
  • Challenging diagnosis due to immunosuppression

Pearl 1: The "Stealth Infection" Phenomenon

Patients on biologics may present with severe infections without classic signs of inflammation. Maintain high clinical suspicion even with normal white blood cell counts and minimal fever response.


Pharmacokinetics in Critical Illness

Drug Survival and Clearance

Critical illness significantly alters biologic pharmacokinetics:

Factors Affecting Drug Levels:

  • Increased vascular permeability → increased volume of distribution
  • Altered protein binding
  • Renal and hepatic dysfunction
  • Extracorporeal therapies (dialysis, ECMO)

Half-Life Considerations in ICU:

  • Short half-life agents (anakinra: 4-6 hours) → rapid clearance, consider continuing for acute inflammatory conditions
  • Medium half-life agents (etanercept: 3-5 days) → moderate persistence
  • Long half-life agents (rituximab: 18-32 days) → prolonged immunosuppression

Hack 1: The "Half-Life Rule"

For decision-making purposes, assume biologics with half-lives >7 days will have significant immunosuppressive effects for at least 4-6 weeks after the last dose, regardless of acute illness.


Clinical Decision-Making Framework

When to Continue Biologics

Scenario 1: Controlled Infection with Stable Patient

  • Well-defined infection source
  • Appropriate antimicrobial therapy initiated
  • Clinical improvement evident
  • Underlying condition requiring biologic is severe/life-threatening

Scenario 2: Inflammatory Conditions Requiring Ongoing Treatment

  • Severe inflammatory bowel disease with bleeding
  • Active rheumatoid arthritis with joint destruction
  • Psoriatic arthritis with severe functional impairment

Example Case: A 45-year-old woman with Crohn's disease on adalimumab presents with pneumonia. After 48 hours of appropriate antibiotics with clinical improvement, continuation of adalimumab may be considered to prevent IBD flare, especially if infection is community-acquired and responding well.

When to Hold/Discontinue Biologics

Absolute Indications:

  • Active, uncontrolled infection
  • Sepsis or septic shock
  • Suspected opportunistic infection
  • New fever of unknown origin
  • Planned major surgery with high infection risk

Relative Indications:

  • Multiple organ dysfunction
  • Prolonged mechanical ventilation
  • Immunocompromised contacts with active infections
  • Geographic exposure to endemic fungi

Oyster 1: The "Autoimmune Paradox"

Stopping biologics may lead to rebound inflammation that can be more dangerous than the original infection risk. Always weigh the consequences of disease flare against infection risk.


Specific Clinical Scenarios

Sepsis and Septic Shock

Management Approach:

  1. Immediately discontinue all biologics
  2. Obtain cultures before antibiotics when feasible
  3. Consider broader antimicrobial coverage
  4. Monitor for opportunistic infections
  5. Consider immunoglobulin levels if prolonged course

Duration of Hold: Continue hold until:

  • Infection source controlled
  • Hemodynamically stable off vasopressors
  • Completing appropriate antimicrobial course
  • No evidence of secondary infections

Perioperative Management

Preoperative Planning:

  • Assess infection risk of procedure
  • Consider timing relative to last biologic dose
  • Evaluate underlying disease activity

High-Risk Procedures (hold biologics):

  • Abdominal surgery with bowel involvement
  • Joint replacement surgery
  • Any procedure with high infection rates

Low-Risk Procedures (may continue):

  • Minor dermatologic procedures
  • Diagnostic procedures
  • Ophthalmologic surgery

Hack 2: The "Surgical Window" Approach

For elective surgery, time procedures to occur at the end of the dosing interval when drug levels are lowest, typically 1-2 weeks after TNF inhibitor administration.


Monitoring and Surveillance Strategies

Infection Surveillance Protocol

Daily Assessment Should Include:

  • Temperature trends (noting blunted fever response)
  • White blood cell differential
  • Inflammatory markers (CRP, procalcitonin)
  • Organ function assessment
  • Wound/device inspection
  • Respiratory symptoms and imaging

Weekly Monitoring:

  • Blood cultures if fever or clinical deterioration
  • Fungal biomarkers (beta-D-glucan, galactomannan) if high risk
  • Viral PCR panels if indicated
  • Imaging studies for occult infections

Laboratory Considerations

Baseline Assessment:

  • Complete blood count with differential
  • Comprehensive metabolic panel
  • Liver function tests
  • Hepatitis B and C screening
  • Quantiferon-Gold or tuberculin skin test
  • Immunoglobulin levels

Ongoing Monitoring:

  • Serial inflammatory markers
  • Lymphocyte subsets if available
  • Immunoglobulin levels (especially with B-cell depleting agents)

Pearl 2: The "Immunologic Memory"

Patients with prior serious infections on biologics have significantly higher risk of recurrent infections. Maintain heightened surveillance for these individuals.


Antimicrobial Considerations

Empiric Therapy Modifications

Broader Coverage Considerations:

  • Extended-spectrum antibiotics for gram-negative coverage
  • Enhanced gram-positive coverage (including MRSA)
  • Antifungal coverage in high-risk patients
  • Consider atypical pathogen coverage

Prophylactic Strategies

High-Risk Patients May Benefit From:

  • Pneumocystis prophylaxis (especially with combination immunosuppression)
  • Antifungal prophylaxis in endemic areas
  • Viral prophylaxis (CMV, HSV) in select cases
  • Bacterial prophylaxis for specific procedures

Duration of Therapy

  • Consider prolonged courses for proven infections
  • Lower threshold for combination therapy
  • Monitor treatment response carefully
  • Consider infectious disease consultation

Hack 3: The "Double Coverage Rule"

In critically ill patients on biologics with suspected bacterial infections, consider dual antibiotic coverage until cultures and sensitivities are available, given the higher risk of treatment failure.


Special Populations and Considerations

Elderly Patients (>65 years)

  • Baseline higher infection risk
  • Slower drug clearance
  • More likely to have comorbidities
  • Consider more conservative approach

Patients with Multiple Comorbidities

  • Diabetes mellitus: Increased fungal infection risk
  • Chronic kidney disease: Altered drug clearance
  • Liver disease: Impaired synthetic function
  • COPD: Higher pneumonia risk

Combination Immunosuppression

Patients receiving multiple immunosuppressive agents require:

  • More aggressive infection surveillance
  • Broader antimicrobial coverage
  • Longer duration of biologic holds
  • Enhanced prophylaxis strategies

Emerging Considerations and Future Directions

COVID-19 and Biologics

The pandemic has highlighted important considerations:

  • TNF inhibitors may not increase COVID-19 severity
  • Some IL-6 inhibitors show promise in severe COVID-19
  • Vaccination responses may be blunted
  • Telemedicine monitoring strategies

Personalized Medicine Approaches

Future developments may include:

  • Pharmacogenomic testing for drug metabolism
  • Biomarkers for infection risk stratification
  • Point-of-care immune function testing
  • Precision dosing strategies

Pearl 3: The "Immune Reconstitution" Timeline

After stopping biologics, immune function recovery varies significantly by agent:

  • TNF inhibitors: 2-6 months
  • B-cell depleting agents: 6-12 months
  • T-cell modulators: 3-6 months

Clinical Pearls and Oysters Summary

Key Pearls

  1. Stealth infections: Maintain high suspicion despite minimal inflammatory signs
  2. Immunologic memory: Prior infections predict future risk
  3. Immune reconstitution timeline: Recovery varies by agent and mechanism

Important Oysters

  1. Autoimmune paradox: Disease flare can be more dangerous than infection risk
  2. Laboratory limitations: Normal inflammatory markers don't rule out serious infection
  3. Timing complexity: Half-life considerations affect decision-making windows

Essential Hacks

  1. Half-life rule: >7 days = significant immunosuppression for 4-6 weeks
  2. Surgical window: Time procedures to end of dosing interval
  3. Double coverage rule: Consider dual antibiotics until cultures available

Evidence-Based Recommendations

Strong Recommendations (High-Quality Evidence)

  1. Discontinue biologics in patients with sepsis or septic shock
  2. Obtain infectious disease consultation for patients with opportunistic infections
  3. Screen for latent tuberculosis before initiating biologics
  4. Monitor for hepatitis B reactivation in at-risk patients

Conditional Recommendations (Moderate-Quality Evidence)

  1. Consider continuing biologics in stable patients with controlled infections
  2. Use broader antimicrobial coverage for empiric therapy
  3. Implement enhanced surveillance protocols in ICU patients
  4. Consider prophylactic antimicrobials in high-risk patients

Expert Opinion (Low-Quality Evidence)

  1. Multidisciplinary team approach for complex cases
  2. Individual risk-benefit assessment for each patient
  3. Consider underlying disease severity in decision-making
  4. Maintain open communication with outpatient specialists

Practical Implementation Strategies

ICU Protocol Development

Essential Components:

  1. Risk stratification criteria
  2. Decision-making algorithms
  3. Monitoring protocols
  4. Consultation triggers
  5. Documentation requirements

Multidisciplinary Team Approach

Key Team Members:

  • Intensivist (primary decision-maker)
  • Infectious disease specialist
  • Rheumatologist/gastroenterologist/dermatologist
  • Clinical pharmacist
  • ICU nurses (monitoring and education)

Quality Improvement Initiatives

Potential Metrics:

  • Time to biologic hold in sepsis
  • Infection rates in biologic patients
  • Appropriate prophylaxis utilization
  • Consultation rates and timing
  • Patient outcomes and length of stay

Conclusion

Biologic therapies in the ICU present a complex clinical challenge that requires careful risk-benefit analysis, vigilant monitoring, and individualized decision-making. While these agents significantly increase infection risk and complicate critical care management, they can be safely managed with appropriate protocols and multidisciplinary collaboration.

The key to success lies in understanding the pharmacokinetics of specific agents, recognizing the altered presentation of infections in immunocompromised patients, and maintaining a high index of suspicion for opportunistic pathogens. As our experience with these agents grows and new biologics enter clinical practice, ongoing education and protocol refinement will be essential.

Ultimately, biologics are neither purely friend nor foe in the ICU setting—they are powerful tools that require expert management to maximize benefits while minimizing risks. The intensivist's role is to navigate this complex landscape with evidence-based decision-making, ensuring optimal outcomes for these challenging patients.


References

  1. Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386(9990):258-265.

  2. Yiu ZZ, Exton LS, Jabbar-Lopez Z, et al. Risk of serious infections in patients with psoriasis on biologic therapies: a systematic review and meta-analysis. J Invest Dermatol. 2016;136(8):1584-1591.

  3. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107(9):1409-1422.

  4. Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1101-1136.

  5. Pappas DA, Hooper MM, Kremer JM, et al. Serious infections in rheumatoid arthritis patients receiving rituximab: results from the rhumadata clinical database and registry. Arthritis Rheum. 2013;65(2):287-294.

  6. Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment. Ann Rheum Dis. 2011;70(9):1559-1566.

  7. Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 2007;56(4):1125-1133.

  8. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011;306(21):2331-2339.

  9. Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011;70(11):1914-1920.

  10. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford). 2013;52(1):53-61.

  11. Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(10):2675-2684.

  12. Salmon-Ceron D, Tubach F, Lortholary O, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis. 2011;70(4):616-623.

  13. Deepak P, Stobaugh DJ, Sherid M, et al. Neurological manifestations in TNF-α inhibitor therapy: an analysis of FDA adverse event reporting system. Inflamm Bowel Dis. 2013;19(8):1693-1701.

  14. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275-2285.

  15. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Ann Rheum Dis. 2009;68(7):1136-1145.

Approach to Tracheostomy Care in the ICU: A Comprehensive Clinical Guide

  Approach to Tracheostomy Care in the ICU: A Comprehensive Clinical Guide Dr Neeraj Manikath , claude.ai Abstract Tracheostomy remains on...